Smith+Nephew announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment.
CENTRIO PRP System can help manage chronic exuding wounds including but not limited to diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers, and tunnelling wounds. Thanks to a National Coverage Determination (NCD) made effective April 2021, autologous PRP for the treatment of chronic non-healing wounds for diabetic patients has CMS coverage, when prepared by devices whose indications include the management of exuding cutaneous wounds, such as diabetic ulcers. The CENTRIO PRP System is designed for point-of-care use in both hospital and physician office settings and the gel can be tailored to fit wound shape, depth, and stage with a single draw of a patient’s blood. CENTRIO PRP System has demonstrated efficacy in two randomized, controlled clinical trials, making it a strong fit in Smith+Nephew’s clinically proven portfolio.
The CENTRIO PRP System will premiere at the Smith+Nephew booth during the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas, Nevada from September 3-6.
Smith+Nephew entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc., a commercial stage medical device company pioneering biodynamic therapies, to market the CENTRIO PRP System in the United States.
